67. Polycystic kidney disease Clinical trials / Disease details

Clinical trials : 216 / Drugs : 219 - (DrugBank : 50) / Drug target genes : 39 - Drug target pathways : 151

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04705051 (ClinicalTrials.gov)	February 9, 2021	8/1/2021	Multicenter, Open-label, Extension Study to Characterize the Long-term Efficacy and Safety of Early Versus Delayed Treatment With Venglustat (GZ/SAR402671) in Patients at Risk of Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Multicenter, Open-label, Extension Study to Characterize the Long-term Efficacy and Safety of Early Versus Delayed Treatment With Venglustat (GZ/SAR402671) in Patients at Risk of Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Congenital Cystic Kidney Disease	Drug: Venglustat GZ402671	Sanofi	NULL	Terminated	18 Years	N/A	All	24	Phase 3	United States;Australia;Belgium;France;Germany;Japan;Korea, Republic of;Netherlands;Romania;Spain
2	NCT03523728 (ClinicalTrials.gov)	October 4, 2018	1/5/2018	A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients	Multicenter, Randomized, Double-blind, Placebo-controlled Two Stage Study to Characterize the Efficacy, Safety, Tolerability and Pharmacokinetics of GZ/SAR402671 in Patients at Risk of Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Polycystic Kidney, Autosomal Dominant	Drug: Venglustat GZ402671;Drug: Placebo	Genzyme, a Sanofi Company	NULL	Terminated	18 Years	55 Years	All	478	Phase 2/Phase 3	United States;Argentina;Australia;Austria;Belgium;Canada;China;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Taiwan;Turkey;United Kingdom